Articles with public access mandates - Rimas LukasLearn more
Not available anywhere: 4
ONGOING CLINICAL TRIALS
M Groves, J DeGroot, I Tremont, A Forman, S Kang, B Pei, W Julie, ...
Neuro-oncology 13 (Suppl 3), iii85-iii91, 2011
Mandates: US National Institutes of Health
Nonmalignant brain tumors
RV Lukas, MM Mrugala
CONTINUUM: Lifelong Learning in Neurology 26 (6), 1495-1522, 2020
Mandates: US National Institutes of Health
Establishment of an acute headache infusion clinic as an alternative for emergency department care
O Reese, C Wright, A Sandoval, B Lebron, A Dhorajiwala, A Shepard, ...
Journal of the Neurological Sciences 423, 117384, 2021
Mandates: US National Institutes of Health
Challenging Cases in Neuro-Oncology
RV Lukas, MM Mrugala, MS Lesniak, JP Chandler
Seminars in Neurology 42 (06), 752-757, 2022
Mandates: US National Institutes of Health
Available somewhere: 64
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
J Zhao, AX Chen, RD Gartrell, AM Silverman, L Aparicio, T Chu, ...
Nature medicine 25 (3), 462-469, 2019
Mandates: US National Science Foundation, US National Institutes of Health, V …
An overview of meningiomas
RA Buerki, CM Horbinski, T Kruser, PM Horowitz, CD James, RV Lukas
Future Oncology 14 (21), 2161-2177, 2018
Mandates: US National Institutes of Health
Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial
EA Chiocca, JS Yu, RV Lukas, IH Solomon, KL Ligon, H Nakashima, ...
Science translational medicine 11 (505), eaaw5680, 2019
Mandates: US Department of Defense, US National Institutes of Health, American Brain …
A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma
P Kumthekar, CH Ko, T Paunesku, K Dixit, AM Sonabend, O Bloch, M Tate, ...
Science translational medicine 13 (584), eabb3945, 2021
Mandates: US Department of Energy, US National Institutes of Health
IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma
E Ladomersky, L Zhai, A Lenzen, KL Lauing, J Qian, DM Scholtens, ...
Clinical cancer research 24 (11), 2559-2573, 2018
Mandates: US National Institutes of Health
Immunosuppressive IDO in cancer: mechanisms of action, animal models, and targeting strategies
L Zhai, A Bell, E Ladomersky, KL Lauing, L Bollu, JA Sosman, B Zhang, ...
Frontiers in immunology 11, 1185, 2020
Mandates: US National Institutes of Health, US Department of Veterans Affairs
Newly diagnosed glioblastoma: a review on clinical management
RV Lukas, DA Wainwright, E Ladomersky, S Sachdev, AM Sonabend, ...
Oncology (Williston Park, NY) 33 (3), 91, 2019
Mandates: US National Institutes of Health
Anti-N-methyl-D-aspartate-receptor encephalitis: diagnosis, optimal management, and challenges
AP Mann, E Grebenciucova, RV Lukas
Therapeutics and clinical risk management, 517-525, 2014
Mandates: US National Institutes of Health
The coincidence between increasing age, immunosuppression, and the incidence of patients with glioblastoma
E Ladomersky, DM Scholtens, M Kocherginsky, EA Hibler, ET Bartom, ...
Frontiers in pharmacology 10, 200, 2019
Mandates: US National Institutes of Health
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial
J Fares, AU Ahmed, IV Ulasov, AM Sonabend, J Miska, C Lee-Chang, ...
The Lancet Oncology 22 (8), 1103-1114, 2021
Mandates: US National Institutes of Health
Pleomorphic xanthoastrocytoma: a brief review
N Shaikh, N Brahmbhatt, TJ Kruser, KL Kam, CL Appin, NR Wadhwani, ...
CNS oncology 8 (3), CNS39, 2019
Mandates: US National Institutes of Health
Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas
MR Drumm, KS Dixit, S Grimm, P Kumthekar, RV Lukas, JJ Raizer, ...
Neuro-oncology 22 (4), 470-479, 2020
Mandates: US National Institutes of Health, Doris Duke Charitable Foundation
Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial
AM Sonabend, A Gould, C Amidei, R Ward, KA Schmidt, DY Zhang, ...
The Lancet Oncology 24 (5), 509-522, 2023
Mandates: US National Institutes of Health
Advanced age increases immunosuppression in the brain and decreases immunotherapeutic efficacy in subjects with glioblastoma
E Ladomersky, L Zhai, KL Lauing, A Bell, J Xu, M Kocherginsky, B Zhang, ...
Clinical Cancer Research 26 (19), 5232-5245, 2020
Mandates: US National Institutes of Health
Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma
L Zhai, A Bell, E Ladomersky, KL Lauing, L Bollu, B Nguyen, M Genet, ...
Clinical cancer research 27 (23), 6514-6528, 2021
Mandates: US National Institutes of Health, UK Medical Research Council, National …
The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy
L Zhai, M Dey, KL Lauing, G Gritsina, R Kaur, RV Lukas, MK Nicholas, ...
Journal of Clinical Neuroscience 22 (12), 1964-1968, 2015
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program